iCAD, Inc.

    iCAD, Inc.

    NNASDAQ:ICAD
    3.87
    USD
    0.00
    (0.00%)
    iCAD, Inc.
    NASDAQ:ICAD
    (Nasdaq Stock Market)

    Recent

    price

    3.87

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2009
    2010
    2011
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    TTM
    USD
    3.09
    2.68
    2.63
    2.62
    3.05
    3.12
    2.65
    1.65
    1.72
    1.54
    1.71
    1.34
    1.36
    0.79
    0.68
    0.74
    0.74
    Revenue per Share
    -0.22
    -0.68
    -3.45
    -0.87
    -0.7
    -0.07
    -2.07
    -0.63
    -0.87
    -0.54
    -0.74
    -0.8
    -0.45
    -0.54
    -0.19
    -0.21
    -0.2
    Basic EPS, GAAP
    0.34
    -0.02
    -0.95
    -0.46
    -0.2
    0.14
    -0.18
    -0.37
    -0.47
    -0.25
    -0.4
    -0.34
    -0.4
    -0.53
    -0.23
    -0.16
    -0.1
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -9.1
    -9.7
    -11.64
    -12.63
    -13.28
    -10.28
    -11.31
    -11.77
    -12.34
    -12.62
    -12.2
    -10.92
    -10.21
    -10.58
    -10.6
    -10.51
    -10.51
    Book Value per Share
    1.79
    0.69
    -0.19
    -0.8
    -1.24
    1.28
    0.91
    0.49
    0.24
    -0.18
    -0.24
    0.96
    1.51
    1.04
    0.97
    0.77
    0.84
    Tangible Book Value per Share
    9
    9
    11
    11
    11
    14
    16
    16
    16
    17
    18
    22
    25
    25
    26
    26
    26
    Basic Weighted Avg Shares
    28
    25
    29
    28
    33
    44
    42
    26
    28
    26
    31
    30
    34
    20
    17
    20
    20
    Sales/Revenue/Turnover
    -7.55
    -26.62
    -50.42
    -19.14
    -5.37
    1.86
    -6.34
    -37.85
    -35.52
    -31.73
    -20.41
    -31.61
    -31.9
    -51.5
    -44.4
    -31.97
    -30.5
    Operating Margin (%)
    2
    2
    3
    3
    2
    4
    3
    2
    1
    1
    1
    1
    1
    1
    - -
    1
    1
    Depreciation Expense
    -2
    -6
    -38
    -9
    -8
    -1
    -32
    -10
    -14
    -9
    -14
    -18
    -11
    -14
    -5
    -6
    -5
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    -7
    -25.33
    -131.18
    -33.15
    -23.01
    -2.3
    -78.08
    -38.34
    -50.73
    -35.19
    -43.24
    -59.3
    -33.43
    -68.96
    -27.99
    -28.64
    -26.77
    Profit Margin (%)
    16
    10
    -1
    7
    - -
    23
    13
    7
    9
    8
    10
    26
    35
    25
    23
    19
    20
    Working Capital
    - -
    - -
    - -
    15
    12
    7
    - -
    - -
    5
    11
    17
    8
    - -
    - -
    - -
    - -
    - -
    LT Debt
    66
    73
    36
    28
    21
    63
    33
    25
    14
    7
    5
    31
    47
    35
    33
    29
    31
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    26
    26
    27
    Market Capitalization
    41
    48
    54

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    Total Current Assets
    26
    26
    28
    Cash, Cash Equivalents & STI
    19
    17
    20
    Accounts Receivable, Net
    5
    7
    7
    Inventories
    1
    1
    1
    Total Current Liabilities
    6
    8
    8
    Payables & Accruals
    3
    3
    4
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    3
    4
    4

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    31.84%
    102.19%
    -14.16%
    Free Cash Flow
    -9.91%
    -3.6%
    -30.12%
    Net Income, GAAP
    306.82%
    -6.68%
    15.87%
    Sales/Revenue/Turnover
    -5.42%
    -6.48%
    13.22%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    4
    4
    4
    5
    17
    2024
    5
    5
    4
    5
    20
    2025
    5
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.15
    -0.07
    -0.05
    0.08
    -0.19
    2024
    -0.05
    -0.07
    -0.07
    -0.03
    -0.21
    2025
    -0.03
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    • ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD

    • iCAD Reports Financial Results for First Quarter Ended March 31, 2025

    • ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD

    • $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of iCAD, Inc. - ICAD

    • ICAD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iCad, Inc. Is Fair to Shareholders

    • iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

    • iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript

    • iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024

    • iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America

    • Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025

    • iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025

    • iCAD Pre-Announces Estimated Q4 2024 Revenue

    • Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions

    • SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations

    • CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024

    • iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024

    • iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript

    • iCAD Reports Financial Results for Third Quarter Ended September 30, 2024

    • iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference

    • iCAD to Participate in the LD Micro Main Event XVII